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Abstract
Introduction. Despite recent advances in diagnosis and pharmacological treatment of cardiovascular diseases, chronic 
heart failure (HF) carries a poor prognosis. The identification of patients at highest risk for early death from HF is of 
special importance. Ergospirometric test is known to be useful in predicting survival and oxygen consumption (maximal/ 
/peak VO2) and minute ventilation-carbon dioxide production relationship (VE/VCO2slope) are the most frequently analyzed 
cardiopulmonary exercise test parameters. The aim of this study was to assess the ability of peak VO2 and VE/VCO2slope 
to predict cardiac-related mortality and cardiac-related hospitalization (MACE, major adverse cardiac event) in patients 
with chronic systolic HF, pre-qualified for heart transplantation.
Material and methods. Forty-five patients (38 men; age 50 ± 8 years) with stable chronic HF (21 coronary artery 
disease, 24 dilated cardiomyopathy), in New York Heart Association functional class II (n. 16)–III (n. 29), with left ven-
tricular ejection fraction (LVEF) below 35% (mean LVEF = 22.7 ± 5.1%), underwent cardiopulmonary exercise testing 
between 2006 and 2012 year.
Results. At the end of follow-up, 5 (11%) patients had died and 17 (38%) had a hospitalization due to CHF exacerbation. 
Peak VO2 was 14.5 ± 5.7 mL/kg/min, VE/VCO2 slope was 35.1 ± 6.1. MACE(+) group had a lower peak VO2 (13.9 ± 
± 6.9 mL/kg/min vs 15.1 ± 4.3, p = NS) and higher VE/VCO2slope (37.2 + 6.0 vs. 33.1 ± 5.6, p = 0.021) than MACE(–) 
group. MACE(+) death group had a lower peak VO2 than MACE(–) group (10.9 ± 1.3 vs. 15.1 ± 4.3, p = 0.045). The 
areas under the receiver operating characteristic curves for predicting MACE at 1 year were 0.68 for peak VO2 and 
0.70 for VE/VCO2slope. The results of Kaplan-Meier analysis revealed a 1-year MACE free survival of 33% in patients with 
VE/VCO2slope > 34.9 and 67% in those with VE/VCO2slope < 34.9 (p = 0.0562) and 20% in patients with peak VO2 
< 11.6 mL/kg/min and 67% in those with peak VO2 > 11.9 mL/kg/min (p = 0.0085).
Conclusions. Both VO2 and VE/VCO2slope, are good prognostic parameters for serious cardiovascular events and improve 
the risk stratification of chronic HF patients.
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VE/VCO2slope > 34] parameters), age above 18 years, writ-
ten consent for participation in the study.
Exclusion criteria were: contraindications to cardiac 
catheterization, pregnancy or breastfeeding, symptoms of 
active infection, contraindications to heart transplantation 
(in addition to hemodynamic contraindications, which 
were assessed during cardiac catheterization). The major 
accident cardiac event (MACE) was defined as cardiovas-
cular death or hospitalization due to exacerbation of HF. 
After reviewing the conditions of participation in the study 
and signing the informed consent patients underwent 
ergospirometric test which was repeated every six months 
(visit 0, after 6 and 12 months).
Statistical analysis
The obtained results were subjected to statistical analy-
sis. The normality of the distribution of variables was 
checked based on the Shapiro-Wilk test. To compare 
variables with a near-normal distribution, Student’s t-test 
for independent variables and dependent variables was 
used. For non-normally distributed variables, the results 
were presented as median and range, and the significance 
of between-groups differences was checked using the 
non-parametric U Mann-Whitney test and the Wilcoxon test. 
Proportions in groups were evaluated with the chi-square 
test (c2). The survival function was estimated according 
to the Kaplan-Meier method. A log-rank test was used to 
compare two survival curves. The degree of relationship 
between the two variables was assessed using Pearson’s 
correlation coefficient, and in the case of non-normally 
distributed variables — with Spearman’s correlation coeffi-
cient. In order to find the best parameters and the optimal 
cut-off value to predict the occurrence of MACE, ROC curves 
were plotted and the area under the curve (AUC) was de-
termined. The sensitivity, specificity, positive and negative 
predictive value, accuracy and likelihood ratio (LR) were 
calculated to assess the prognostic value of the obtained 
cut-off values. P-value threshold for statistical significance 
was 0.05. Results close to this level, which may be the 
inspiration for further research, are presented as being at 
the level of statistical trend. P-value of 0.1 was assumed 
to be the threshold of statistical trend. The calculations 
were performed using the STATISTICA v. 10.0 PL software 
(StatSoft, Inc.).
Results
Of the 45 patients enrolled in the study, 22 (49.0%) had 
a composite end-point — MACE(+) — over a 12-month per-
iod, with 17 (38.0%) patients experiencing HF exacerbation 
and 5 (11.0%) patients died. No patient had a heart trans-
plant at that time. Table 1 presents the initial results of the 
evaluated parameters in the MACE(–) and MACE(+) groups. 
Introduction
Despite considerable progress in the diagnosis and treat-
ment of cardiovascular diseases, heart failure (HF) remains 
one of the biggest problems of modern medicine and the 
entire health care system. Patients with advanced HF 
are characterized by a high risk of cardiovascular death; 
therefore, a very important role is played by prognostic 
factors, which allow identification of the subgroup of pa-
tients requiring the most intensive treatment, including 
the preparation for heart transplantation. The aim of the 
study was to prospectively assess the prognostic value of 
ergospirometric parameters (peak/maximum oxygen con-
sumption [VO2peak/VO2max] and the ventilatory equivalent 
for carbon dioxide, i.e. the relationship between minute 
ventilation and carbon dioxide production [VE/VCO2slope]) in 
the group of patients pre-qualified for heart transplantation 
with chronic systolic HF caused by ischemic heart disease 
or non-ischemic dilated cardiomyopathy.
Material and methods
Forty-five patients (7 women and 38 men aged 27–63 
years) with advanced systolic HF (mean left ventricular 
ejection fraction assessed by echocardiography = 22.7 ± 
± 5.1%) in a stable clinical state were prospectively ana-
lyzed: 16 patients (35%) in New York Heart Association 
(NYHA) functional class II and 29 patients (65%) in NYHA 
class III, hospitalized to consider the pre-qualification to 
heart transplantation. The diagnosis of chronic HF was 
based on the criteria of the European Society of Cardiology 
(ESC): HF symptoms with objectively confirmed impairment 
of cardiac systolic function at rest. The patients were cardi-
opulmonary stable and received fixed doses of medication 
at least 2 weeks prior to the study. The treatment was 
modified depending on the clinical condition during further 
outpatient follow-up. The patients were taking the following 
medications: beta-blockers — 100%, angiotensin-converting 
enzyme (ACEI) inhibitors — 78.3%, angiotensin receptor 
blockers (ARB) — 32.6%, spironolactone or eplerenone — 
91.3%, and loop diuretics — 82.6%. All patients previously 
underwent coronary angiography. Ischemic cardiomyopathy 
was diagnosed in 21 patients and non-ischemic cardiomy-
opathy — in 24 patients. Coexisting atrial fibrillation was 
found in 17 patients (37.7%), diabetes in 11 (24.4%), and 
arterial hypertension in 11 (24.4%). Twenty-six patients 
(57.7%) were smokers. At the time of inclusion, 16 patients 
(35.6%) had implantable cardioverter-defibrillators; none 
of the patients had cardiac resynchronization therapy 
defibrillator.
Inclusion criteria were also: poor prognosis for survival 
(assessed on the basis of clinical data, echocardiographic 
[LVEF < 35%] and/or ergospirometric [VO2peak < 12 mL/kg/min, 
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divided and the survival function was estimated using the 
Kaplan-Meier method. There was a statistically significant 
difference between the survival curves for patients in the 
VO2 subgroups (p = 0.0085) (Figure 1).
The calculated relative risk of RR = 2.4 indicates that 
the risk of MACE in the group of patients with VO2 below 
11.6 mL/kg/min is 2.4 times higher than in the group 
with VO2 over 11.6 mL/kg/min (95% CI 1.36–4.23; 
p = 0.0024). There was a difference between the survival 
curves for patients in the VE/VCO2slope subgroups show-
ing a trend towards statistical significance (p = 0.0562) 
(Figure 2).
The mean baseline VO2 values were not significantly differ-
ent (p = 0.473) between the MACE(–) and MACE(+) patients, 
but in the MACE(+) death subgroup mean VO2 value was 
statistically significantly lower compared with the MACE(–) 
group (p = 0.045). The mean baseline VE/VCO2 value in 
the MACE(–) group was statistically significantly lower than 
the mean VE/VCO2 value in the MACE(+) group (p = 0.021).
In order to assess the usefulness of VO2 and VE/CO2 
measurements in determining the probability of MACE oc-
currence, receiver operating characteristics (ROC) curves 
were plotted. They are created based on the determined 
sensitivity and specificity for different cut-off points. The 
area under the curve (AUC) above the diagonal shows 
the classification quality of the diagnostic variable. The 
analysis of ROC curves makes it possible to determine the 
optimal values of the analyzed parameters (cut-off points) 
that best divide the studied group into a subgroup in which 
the risk of MACE is higher and a subgroup in which the 
risk of MACE is lower. Table 1 presents baseline values of 
the parameters evaluated in the MACE(–) and MACE(+) 
groups and Table 2 presents the ROC curve analysis results 
in which the area under the curve, specificity, accuracy, 
positive and negative predictive value and likelihood ratio 
(LR) were calculated for individual parameters and their 
cut-off values (Tables 1, 2).
In the presented work, the AUC values for the evalu-
ated parameters indicate the mean value of the deci-
sion-making models based on them. The slightly higher 
AUC was associated with the VE/VCO2slope measurement 
than with VO2 (0.70 vs 0.68, respectively). On the basis 
of the determined cut-off points, the studied group was 
Table 1. Baseline values of the evaluated parameters in the MACE(–) and MACE(+) groups
MACE(+) N = 22 MACE(–)         N = 23 p
VO2 MACE(+) total 13.9 ± 6.9 15.1 ± 4.3 NS
MACE(+) HF exacerbation 14.7 ± 7.6 15.1 ± 4.3 NS
MACE(+) death 10.9 ± 1.3 15.1 ± 4.3 0.045
VE/VCO2slope MACE(+) total 37.2 ± 6.0 33.1 ± 5.6 0,021
MACE(+) HF exacerbation 36.5 ± 5.5 33.1 ± 5.6 NS
MACE(+) death 139.8 ± 7.8 33.1 ± 5.6 0,032
MACE — major adverse cardiac event; NS — not significant; VO2 — peak/maximum oxygen consumption; VE/VCO2slope — minute ventilation-carbon dioxide production relationship
Table 2. Predictive value of the determined cut-off points of the evaluated parameters
Parameter Cut-off value AUC Sensitivity Specificity Accuracy Positive  
predictive value
Negative  
predictive value
LR
VO2 11.6 0.678 0.591 0.870 0.733 0.813 0.690 4.5
VE/VCO2slope 34.9 0.696 0.636 0.696 0.667 0.667 0.667 2.1
VO2 — peak/maximum oxygen consumption; VE/VCO2slope — minute ventilation-carbon dioxide production relationship; AUC — area under curve; LR — likelihood ratio
Figure 1. Kaplan-Meier survival functions for groups distinguished 
based on the determined cut-off value of peak/maximum oxygen 
consumption (VO2); MACE — major adverse cardiac event
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The calculated relative risk of RR = 2.0 indicates that 
the risk of MACE in the group of patients with VE/VCO2 over 
34.9 is 2 times higher than in the group of patients with 
VE/VCO2 below 34.9 (95% CI 1.05–3.80; p = 0.0342). In 
addition, in our study, the prognostic value of the combined 
ergospirometric parameters was evaluated; the analysis 
was carried out in two ways — the first one compared 
the subgroup of patients with VO2 results over 11.6 mL/ 
/kg/min + VE/VCO2slope below 34.9 vs other patients (i.e. 
“better” VO2 and VE/VCO2 result vs other results). The 
calculated risk of MACE in the group of patients with 
a worse result was 2.5 times higher than in the group 
of patients with a better result (95% CI 1.31–4.90; 
p = 0.0055) (Figure 3).
The second way was to divide the patients into a sub-
group with “the worst” results: VO2 below 11.4 mL/kg/ 
/min + VE/VCO2slope over 34.9, and the subgroup with “the 
best” results: VO2 over 11.4 mL/kg/min + VE/VCO2 be-
low 34.9 (i.e. the comparison of two extreme groups). 
The risk of MACE in the group of patients with the worst 
results turned out to be 4.1 times higher than in the group 
of patients with the best results (95% CI 1.34–12.35; 
p = 0.0131) (Figure 4). 
Discussion
The most frequent causes of HF are ischemic heart disease 
and hypertension [1], while in the younger population the 
dominating factor is dilated cardiomyopathy (DCM), the 
third most frequent cause of HF in Western populations [2]. 
In the presented study, a selected group of patients with 
chronic systolic HF in the course of coronary disease and 
non-ischemic cardiomyopathy was observed. The occur-
rence of adverse cardiac events in the study group during 
the 12-month follow-up was found in 49% of patients: 
17 patients (38.0%) had HF exacerbation and 6 patients 
(11.0%) died. Minute ventilation-carbon dioxide production 
relationship proved to be a significant risk factor for the 
endpoint — a significantly higher mean VE/VCO2slope value 
was found in MACE patients (+) compared with the MACE(–) 
group (p = 0.02). Similar results were obtained by Mejhert 
et al. [3] who found that in patients with HF (n = 67, NYHA 
class II and III, mean LVEF = 36%) VE/VCO2 and peak 
VO2 were mortality predictors. According to the authors, 
VE/VCO2slope with a cut-off value of 45 may be the most 
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Figure 2. Kaplan-Meier survival functions for groups distinguished 
based on the determined cut-off value of the ventilatory equivalent 
for carbon dioxide (VE/VCO2 slope); MACE — major adverse cardiac 
event
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Figure 3. Kaplan-Meier survival functions for groups distinguished 
based on the determined cut-off values of peak/maximum oxygen 
consumption (VO2) and ventilatory equivalent for carbon dioxide 
(VE/VCO2) (“better” VO2 and VE/VCO2 result vs other results); 
MACE — major adverse cardiac event
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Figure 4. Kaplan-Meier survival functions for groups distinguished 
based on the determined cut-off values of peak/maximum oxygen 
consumption (VO2) and ventilatory equivalent for carbon dioxide 
(VE/VCO2) (2 extreme groups); MACE — major adverse cardiac 
event
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useful tool in determining the risk of death (better than 
LVEF). However, this is a rather isolated opinion, because 
the acknowledged predictive cut-off value of VE/VCO2 is 
34 (or 35) and it seems that the value exceeding 45 is of 
little clinical significance. In the authors’ own study, the dif-
ferential value between the MACE(+) and MACE(–) groups 
was VE/VCO2 equal to 34.9, which is almost identical to 
the abovementioned most frequently cited cut-off point 
[4]. Similar results were obtained by Arena [5] and Sarullo 
[6] who proposed cut-off points slightly higher for VO2 and 
lower for VE/VCO2slope, which probably results from milder 
echocardiographic criteria of inclusion (LVEF < 45%). Also 
in a study conducted in the Asian population, assessing 
the prognostic value of VE/VCO2slope, almost identical AUCs 
were obtained as in our study — 0.67 for mortality and 0.68 
for hospitalization due to exacerbation of HF. The cut-off 
values for differentiating between MACE(+) and MACE(–) 
groups were also similar, namely: not less than 39.3 for 
mortality and at least 32.9 for hospitalization due to HF 
exacerbation [7]. Poggio et al. [8] performed a meta-anal-
ysis summarizing available data on the assessment of 
the prognostic value of VE/VCO2. MACE was defined as 
death, the need for transplantation or implantation of a left 
ventricular assist device. In the final analysis, the AUC for 
VE/VCO2 was 0.75, which is similar to the result obtained in 
our study. In addition, the prognostic value of VE/VCO2slope 
was slightly higher than that of VO2, which is also concor-
dant with our observations.
The prognostic value of VO2 in patients with HF has 
been confirmed in many observations [9–11], and the 
VO2 below 14 mL/kg/minute was considered an accept-
able criterion for cardiac transplantation in outpatient 
patients already in 1991 [12]. The analysis of peak 
oxygen consumption in our study showed a statistically 
significant relationship only to the MACE(–) and MACE(+) 
death groups (15.1 vs. 10.9, p < 0.05), and the AUC value 
for VO2 was 0.70.
Similar results were obtained by Meyer [13] — in 
a group of 244 patients with congestive HF (LVEF = 22 ± 
± 10%) peak oxygen consumption in survivors vs fatal out-
come was 15.1 vs. 12.9 (p < 0.05), while AUC for VO2peak 
was 0.73 [13].
Studies by Gitt [14] and Arena [15] assessed the prog-
nostic value of the combined ergospirometric parameters. 
According to expectations and the results of our own ob-
servations, the largest number of incidents was observed 
in the subgroup with the lowest oxygen consumption 
and at the same time the highest VE/VCO2slope. The cut- 
-off value for VO2 estimated in our study based on ROC 
curves was 11.6 mL/kg/min, which has been confirmed 
by the guidelines of the International Society for Heart 
and Lung Transplantation (ISHLT), where the VO2 value 
of less than or equal to 12 mL/kg/min is considered as 
the indication for cardiac transplantation in patients with 
chronic heart failure treated with beta-blockers [16]. Our 
study showed that VE/VCO2slope and VO2 in the MACE(+) 
death subgroup of patients were statistically significant 
risk factors for MACE.
Conclusions
Both peak/maximum oxygen consumption and minute 
ventilation-carbon dioxide production relationship are 
important predictors of cardiovascular death or hospitali-
zation due to exacerbation of HF. The prognostic value of 
both parameters proved to be comparable, with a slight 
advantage of VE/VCO2slope. The combined assessment of 
VO2 and VE/VCO2slope can be considered as an additional 
valuable tool in determining prognosis in patients with 
heart failure.
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Streszczenie
Wstęp. Mimo ostatnich osiągnięć w diagnostyce i terapii chorób układu sercowo-naczyniowego rokowanie w niewydolności 
serca (HF) pozostaje niezadowalające, dlatego identyfikacja chorych z grupy najwyższego ryzyka wczesnego zgonu ma szcze-
gólne znaczenie. Wysiłkowy test ergospirometryczny jest uznanym badaniem w diagnostyce HF, a szczytowe/maksymalne zu-
życie tlenu (VO2peak/VO2max) oraz ekwiwalent wentylacyjny dwutlenku węgla (VE/VCO2slope) to najczęściej oceniane parametry.
Celem pracy była prospektywna, roczna ocena wpływu parametrów ergospirometrycznych (VO2peak/max oraz VE/VCO2slope) 
na wystąpienie punktu końcowego (MACE), definiowanego jako zgon z przyczyn sercowo-naczyniowych lub hospitaliza-
cja z powodu zaostrzenia HF u chorych z przewlekłą skurczową HF, kwalifikowanych wstępnie do transplantacji serca.
Materiał i metody. Prospektywnej obserwacji poddano 45 pacjentów (38 mężczyzn, średni wiek 50 ± 8 lat) z rozpo-
znaną skurczową niewydolnością serca (u 21 osób etiologia niedokrwienna, u 24 osób nieniedokrwienna) w II (n = 16) 
i III (n = 29) klasie według New York Heart Association, ze zredukowaną frakcją wyrzutową lewej komory (LVEF) poniżej 
35% (średnia LVEF = 22,7 ± 5,1%). U każdego pacjenta wyjściowo wykonano badanie ergospirometryczne z oceną VO2 
i VE/VCO2slope.
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Wyniki. W okresie 12 miesięcy u 22 (49,0%) pacjentów obserwowano wystąpienie złożonego punktu końcowego 
(MACE+), w tym u 17 (38,0%) wystąpiło zaostrzenie HF, a 5 (11,0%) pacjentów zmarło. Szczytowe/maksymalne VO2 
wyniosło 14,5 ± 5,7 ml/kg mc./min, zaś VE/VCO2slope 35,1 ± 6,1. W grupie MACE(+) obserwowano niższe wartości 
VO2 (13,9 ± 6,9 ml/kg mc./min v. 15,1 ± 4,3; p = NS) i wyższy VE/VCO2slope (37,2 + 6,0 v. 33,1 ± 5,6; p = 0,021) niż 
w grupie MACE(–). Podgrupa MACE(+) zgon miała istotnie statystycznie niższą wartość VO2 niż MACE(–) (10,9 ± 1,3 
v. 15,1 ± 4,3; p = 0,045).
Na podstawie analizy krzywych ROC wyznaczono dla VO2 i VE/VCO2slope pole pod krzywą, odpowiednio, 0,68 i 0,70; 
p < 0,05). Oszacowana metodą Kaplana-Meiera funkcja przeżycia wykazała roczne przeżycie wolne od wystąpienia 
MACE u 33% pacjentów z VE/VCO2slope ponad 34,9 i 67% u tych z VE/VCO2slope poniżej 34,9 (p = 0,0562) oraz u 20% 
pacjentów z VO2 poniżej 11,6 ml/kg mc./min i 67% u tych z VO2 ponad 11.9 ml/kg/min (p = 0,0085).
Wnioski. Zarówno VO2 jak i VE/VCO2slope są istotnymi czynnikami rokowniczymi wystąpienia zgonu z przyczyn sercowych 
bądź hospitalizacji z powodu zaostrzenia HF. Wartość rokownicza obu parametrów okazuje się porównywalna z niewielką 
przewagą VE/VCO2slope. Analiza połączonych parametrów ergospirometrycznych ma większą wartość prognostyczną niż 
osobna ocena VO2 oraz VE/VCO2slope.
Słowa kluczowe: ergospirometria, czynniki rokownicze, niewydolność serca
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